Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC™s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Intellectual Property In India: Novartis Gleevec Suit Is First Challenge To Law Restricting New Formulation Patents (Part 2 of 3)

This article was originally published in PharmAsia News

Executive Summary

Novartis' lawsuit to gain a patent for a new formulation of Gleevec is the first legal challenge to Section 3(d) of the Indian Patent Act, which seeks to bar "evergreening" by restricting patents for minor improvements to old formulations

You may also be interested in...



Intellectual Property In India: Novartis Gleevec Patent Battle Will Go On Without Government Document Supporting “Evergreening” (Part 1 of 3)

In the first part of a three-part series on difficulties faced by drug manufacturers in patenting products in India, “The Pink Sheet” DAILY looks at the uphill battle Novartis faces in its lawsuit against the government to obtain a patent for a new formulation of Gleevec.

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

SC066054

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel